Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials,Clinical Journal of the American Society of Nephrology

当前位置： X-MOL 学术 › Clin. J. Am. Soc. Nephrol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials
Clinical Journal of the American Society of Nephrology ( IF 8.5 ) Pub Date : 2024-04-16 , DOI: 10.2215/cjn.0000000000000470
Robert A. Fletcher ₁ , William G. Herrington _{2,

3,

4} , Rajiv Agarwal ₅ , Kaitlin J. Mayne _{2,

6} , Clare Arnott _{1,

7,

8} , Meg J. Jardine _{9,

10} , Kenneth W. Mahaffey ₁₁ , Vlado Perkovic _{1,

12} , Natalie Staplin _{2,

3} , David C. Wheeler _{1,

13} , Glenn M. Chertow ₁₄ , Hiddo J. L. Heerspink ₁₅ , Brendon L. Neuen _{1,

16}

Affiliation

The George Institute for Global Health, UNSW, Sydney, New South Wales, Australia
Medical Research Council Population Health Research Unit at the University of Oxford, Nuffield Department of Population Health (NDPH), University of Oxford, UK
Clinical Trial Service Unit and Epidemiologic Studies Unit (CTSU), NDPH, University of Oxford, UK
Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Indiana University School of Medicine and VA Medical Center, Indianapolis, IN, USA
School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK
Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
NHMRC Clinical Trials Centre, University of Sydney, New South Wales, Australia
Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, USA
Faculty of Medicine and Health, UNSW, Sydney, New South Wales, Australia
Department of Renal Medicine, University College London, London, UK
Departments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, CA, USA
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Clinical Trial registry name and registration number: ClinicalTrials.gov Identifiers: NCT02065791 (CREDENCE), NCT03036150 (DAPA-CKD), NCT03594110 (EMPA-KIDNEY).

中文翻译：

钠-葡萄糖协同转运蛋白 2 抑制剂对 CKD 患者特定原因心血管死亡的影响：CKD 进展试验的荟萃分析

临床试验注册名称和注册号：ClinicalTrials.gov 标识符：NCT02065791 (CREDENCE)、NCT03036150 (DAPA-CKD)、NCT03594110 (EMPA-KIDNEY)。

更新日期：2024-04-16

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>